Washington, D.C. — For years, a maddening gap has existed between when the federal government approves a new medical device and when Medicare patients can actually get one. It could take more than a year — sometimes much longer — after FDA approval before Medicare would officially cover it. That’s about to change.
The Centers for Medicare & Medicaid Services and the U.S. Food and Drug Administration jointly announced a new initiative called the RAPID coverage pathway — short for Regulatory Alignment for Predictable and Immediate Device — on April 23. It’s designed to close that gap dramatically, potentially cutting the wait from over a year to just two months.
For nursing homes, whose residents are overwhelmingly Medicare beneficiaries, that could mean faster access to technologies that directly affect care outcomes.
How It Works
The RAPID pathway brings CMS into the picture much earlier in the device development process. Under the old system, FDA handled approval and CMS handled coverage — sequentially, with little coordination. Manufacturers often spent a year or more navigating two separate federal processes after already completing clinical trials.
Under RAPID, CMS joins conversations between the FDA and device makers early in development. That means clinical trials can be designed to satisfy both regulatory approval and Medicare coverage standards at the same time, cutting down duplicated work and delays.
Once a device receives FDA market authorization, CMS will issue a proposed national coverage decision the same day. After a 30-day public comment period, Medicare coverage and payment could follow within just two months of approval — compared to a year or more under the old process.
CMS Administrator Dr. Mehmet Oz called it a way for the two agencies to function “as a single team” to get life-changing technologies to patients faster.
Who Qualifies
The RAPID pathway is limited to FDA-designated Class II and Class III Breakthrough Devices — meaning devices that address serious or life-threatening conditions with no comparable alternatives. About 40 devices are estimated to currently qualify, with potentially 20 more through a related program.
Eligibility requires that the device’s clinical trial must enroll Medicare beneficiaries and measure health outcomes that both agencies have agreed are relevant. Evidence generated for FDA review would serve double duty, informing Medicare’s coverage decision as well.
The existing Transitional Coverage for Emerging Technologies pathway is being paused while CMS focuses on implementing RAPID.
Why It Matters for Nursing Homes
Nursing home residents tend to be older, sicker, and dealing with more complex conditions than the general Medicare population. They’re also disproportionately reliant on Medicare coverage for access to newer therapies.
When cutting-edge devices are approved but not yet covered, it’s typically nursing homes and their patients who wait the longest — facilities can’t afford to provide uncovered care, and residents can’t pay out of pocket. That gap between what Medicare promises and what it actually delivers has long been a frustration for operators and families alike.
A faster, more predictable coverage timeline could change that calculus. If manufacturers know Medicare coverage arrives within roughly 60 days of approval, it may also encourage more innovation aimed squarely at the Medicare population — including those living in long-term care.
A proposed procedural notice for RAPID will be published in the Federal Register, with a 60-day public comment window before the pathway formally takes effect.
